Treatment and outcome analysis of 639 relapsed non-hodgkin lymphomas in children and adolescents and resulting treatment recommendations
Author
dc.contributor.author
Burkhardt, Birgit
Author
dc.contributor.author
Taj, Mary
Author
dc.contributor.author
Garnier, Nathalie
Author
dc.contributor.author
Minard Colin, Veronique
Author
dc.contributor.author
Hazar, Volkan
Author
dc.contributor.author
Mellgren, Karin
Author
dc.contributor.author
Osumi, Tomoo
Author
dc.contributor.author
Fedorova, Alina
Author
dc.contributor.author
Myakova, Natalia
Author
dc.contributor.author
Verdu Amoros, Jaime
Author
dc.contributor.author
Andres, Mara
Author
dc.contributor.author
Kabickova, Edita
Author
dc.contributor.author
Attarbaschi, Andishe
Author
dc.contributor.author
Chiang, Alan Kwok Shing
Author
dc.contributor.author
Bubanska, Eva
Author
dc.contributor.author
Donska, Svetlana
Author
dc.contributor.author
Hjalgrim, Lisa Lyngsie
Author
dc.contributor.author
Wachowiak, Jacek
Author
dc.contributor.author
Pieczonka, Anna
Author
dc.contributor.author
Uyttebroeck, Anne
Author
dc.contributor.author
Lazic, Jelena
Author
dc.contributor.author
Loeffen, Jan
Author
dc.contributor.author
Buechner, Jochen
Author
dc.contributor.author
Niggli, Félix
Author
dc.contributor.author
Csoka, Monika
Author
dc.contributor.author
Krivan, Gergely
Author
dc.contributor.author
Palma Behnke, Julia Irene
Author
dc.contributor.author
Burke, G. A. Amos
Author
dc.contributor.author
Beishuizen, Auke
Author
dc.contributor.author
Koeppen, Kristin
Author
dc.contributor.author
Mueller, Stephanie
Author
dc.contributor.author
Herbrueggen, Heidi
Author
dc.contributor.author
Woessmann, Wilhelm
Author
dc.contributor.author
Zimmermann, Martin
Author
dc.contributor.author
Balduzzi, Adriana
Author
dc.contributor.author
Pillon, Marta
Admission date
dc.date.accessioned
2022-04-06T19:15:41Z
Available date
dc.date.available
2022-04-06T19:15:41Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Cancers 2021, 13, 2075
es_ES
Identifier
dc.identifier.other
10.3390/cancers13092075
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/184752
Abstract
dc.description.abstract
Simple Summary: Despite very poor survival, controversies remain in the treatment for refractory
or relapsed non-Hodgkin lymphoma (r/r NHL) in children and adolescents. The current project identifies
and reports international experience on re-induction treatment of r/r NHL, hematopoietic stem
cell transplantation, risk factors associated with outcome, and suggests treatment recommendations.
Despite poor survival, controversies remain in the treatment for refractory or relapsed
pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international
experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT),
risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria
were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic
large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000.
Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was
34 2% with highly significant differences according to NHL subtypes: 28 3% for 254 Burkitt
lymphoma/leukemia, 50 6% for 98 diffuse large B-cell lymphomas, 57 8% for 41 primary
mediastinal large B-cell lymphomas, 27 3% for 177 T-lymphoblastic lymphomas, 52 10% for 34
precursor-B-cell lymphoblastic lymphomas and 30 9% for 35 patients with rare NHL subtypes.
Subtype-specific factors associated with survival and treatment recommendations are suggested.
There were no survivors without HSCT, except in few very small subgroups. Conclusions: There
is an urgent need to further improve survival in r/r NHL. The current study provides the largest
real-world series, which underlines the role of HSCT and suggests treatment recommendations.
es_ES
Patrocinador
dc.description.sponsorship
Deutsche Kinderkrebsstiftung DKS 2014.11A/B
DKS 2016.24A/B
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
MDPI
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States